Qiagen takeover interest firms up as FDA clears new test
Takeover interest at $50+ per share Private equity firms including EQT, Advent and KKR are exploring a buyout of Qiagen at around $50 a share, well above its recent price near $41.50. A takeover at that level would hand shareholders a large premium, so the stock jumped on the news.
This is the main force behind Qiagen's move and the core of the period's news.
Formal due diligence begins with two buyers Two potential buyers have started formal due diligence on Qiagen, with a sale price around $50 a share being discussed. This shows the takeover talks are progressing beyond early interest, which supports the stock, though the buyers could still walk away and Qiagen could stay independent.
It is a new, concrete step that advances the takeover story and affects the price.
First FDA clearance for bloodstream infection panel Qiagen won FDA clearance for its QIAstat-Dx bloodstream infection panel, letting it enter the U.S. market for rapid sepsis testing. This opens a new revenue stream and supports future growth, giving fundamental backing to the stock beyond takeover talk.
It is a new product milestone that adds real business value and supports the share price.
New CEO named amid takeover talks Qiagen appointed Jonathan Pratt as CEO from September 1, succeeding Thierry Bernard, while takeover discussions continue. A leadership change during a sale process adds uncertainty, but the company reaffirmed its 2026 outlook, so the effect on the stock is mixed.
It is a new event that could sway investor confidence and the takeover outcome.